logo

For the Inventor, By the Inventor

The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Patent No.:

US 9446039 B1

PDFFull Text
Date of Patent:
Sep. 20, 2016

Filed:

Aug. 27, 2013

Aminoheteroaryl compounds as mth1 inhibitors

Applicant:

Cemm—forschungszentrum Für Molekulare Medizin Gmbh, Vienna, AT;

Inventors:

Kilian Huber, Vienna, AT;

Giulio Superti-Furga, Vienna, AT;

Assignee:

CeMM Forschungszentrum für Molekulare Medizin GmbH, Vienna, AT;

Attorney:

Parker Highlander PLLC

Primary Examiner:

Heidi Reese

Int. Cl.
CPC ...
A61K 31/44 (2006.01); A61K 31/4545 (2006.01); A61K 45/06 (2006.01); G01N 33/573 (2006.01); G01N 33/50 (2006.01); G01N 33/94 (2006.01);
U.S. Cl.
CPC ...
A61K 31/4545 (2013.01); A61K 45/06 (2013.01); G01N 33/5011 (2013.01); G01N 33/573 (2013.01); G01N 33/94 (2013.01); G01N 2333/4704 (2013.01); G01N 2333/914 (2013.01); G01N 2430/00 (2013.01); G01N 2500/04 (2013.01); G01N 2800/52 (2013.01);
Abstract

The present invention relates to an (S)-enantiomer of an aminoheteroaryl compound for use in treating and/or preventing cancer in a subject. The invention further relates to a pharmaceutical composition comprising said compound. Another aspect of the invention is directed to an in vitro method for determining the effectiveness of said (S)-enantiomer of an aminoheteroaryl compound, or said pharmaceutical composition, the method comprising the steps of: (a) obtaining a cell or tissue sample from a subject; and (b) determining the subject's NUDT1/MTH1-status; wherein a NUDT1/MTH1-positive cell or tissue sample is indicative of an effective treatment and/or prevention of cancer. In addition, provided herein is a screening method for identifying a target of an (S)-enantiomer of an aminoheteroaryl compound. Furthermore, in context of this invention, the herein described compounds inhibit the biological activity of MTH1.

Find Patent Forward Citations

Huber, Kilian. (2016). Aminoheteroaryl compounds as mth1 inhibitors (U.S. Patent No. 9446039). U.S. Patent and Trademark Office. https://idiyas.com/patent/badge/9446039

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Loading…